Refining methods
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- QBD QS IP
- Filing Date
- 2024-07-11
- Publication Date
- 2026-06-11
Smart Images

Figure 0007873274000005 
Figure 0007873274000006 
Figure 0007873274000007
Abstract
Claims
1. A method for purifying antibodies that have specificity for blood group antigens, A step of bringing an antibody source and red blood cells expressing blood group antigens into contact under conditions that enable the blood group antigens expressed by the red blood cells to bind to blood group antigen-specific antibodies in the source, and Steps to isolate bound antibodies Includes, The method wherein the method does not utilize cell membrane fragments or stromas, the source is blood, blood products, serum and / or plasma, and the red blood cells and the source are of the same species.
2. The method according to claim 1, wherein the source is derived from or provided by subjects willing to donate blood (blood donors) and / or subjects immunized to produce antibodies against specific targets.
3. The method according to claim 1 or 2, wherein the antibody is a polyclonal antibody.
4. The method according to any one of claims 1 to 3, wherein the red blood cells are not conjugated to a support, supporting substrate, or polymer.
5. The method according to any one of claims 1 to 4, wherein the step of isolating the bound antibody involves dissociating and / or eluting the antibody adsorbed to or bound to red blood cells.
6. The method according to claim 5, wherein the dissociation and / or elution procedure includes heating, rapid freezing / thawing, ultrasonic bath, cell lysis, acid-based elution / dissociation, chilled acid, organic solvent, xylene, chloroform, improved heating / stirring, and chloroquine diphosphate.
7. The method according to claim 5 or 6, wherein the step of isolating the bound antibody involves contacting the antibody / cell complex with an elution buffer.
8. The method according to claim 7, wherein the elution buffer is formulated to cause dissociation of the antibody by acid elution.
9. The method according to claim 7 or 8, wherein the elution buffer comprises or essentially comprises glycine-HCl and NaCl.